Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy

doi:10.3748/wjg.v21.i32.9598

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8339)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

546

WORD

214

HTML

3510

Figures (1-4)

242

Tables (1-5)

274

Sum=4786

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1164

Download

2389

Sum=3553

Aug 28, 2015 (publication date) through Jan 2, 2025

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Aug 28, 2015; 21(32): 9598-9606
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9598

Table 2 Virological, biochemical and serologic outcomes after long-term treatment in both entecavir and lamivudine arms n (%)

	ETV	LAM ± ADV	P-value
n	19	23
HBV DNA < 1000 IU/mL	18 (94.74)	22 (95.65)	0.8897
HBV DNA < 60 IU/mL	10/13 (76.92)	11/16 (68.75)	0.6243
ALT ≤ 1 × upper limit of normal	18 (94.74)	17 (73.91)	0.0715
HBeAg loss/HBeAg positive at baseline	6/13 (46.15)	10/14 (71.43)	0.1817
HBe seroconversion/HBeAg positivity at baseline	5/13 (38.46)	6/14 (42.86)	0.8163
HBsAg loss	0 (0)	0 (0)	-

ETV: Entecavir; LAM: Lamivudine; ADV: Adefovir; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen.

Citation: Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol 2015; 21(32): 9598-9606
URL: https://www.wjgnet.com/1007-9327/full/v21/i32/9598.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i32.9598